Molecular structure of AZD4547, CAS Number: 1035270-39-3
AZD4547 (CAS 1035270-39-3)
See product citations (6)
Alternate Names:
N-(5-(3,5-dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3S,5R)-3,5-dimethylpiperazin-1-yl)benzamide
Application:
AZD4547 is a novel selective FGFR inhibitor targeting Flg (FGFR1), Bek (FGFR2), and FGFR-3
CAS Number:
1035270-39-3
Purity:
>99%
Molecular Weight:
463.57
Molecular Formula:
C26H33N5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AZD4547 is a compound that has been the subject of extensive research due to its role as a selective inhibitor of the fibroblast growth factor receptors (FGFRs). In research applications, AZD4547 is used to study the signal transduction pathways mediated by FGFRs, which are involved in processes such as cell differentiation, proliferation, and migration. By inhibiting these receptors, AZD4547 helps scientists understand the consequences of disrupted FGFR signaling, which is implicated in various biological phenomena. In addition, this compound serves as a tool for elucidating the molecular mechanisms underlying angiogenesis and tissue repair, as FGFRs play a role in these processes. Researchers also utilize AZD4547 in the study of tumor biology, as aberrant FGFR activity has been associated with the development and progression of certain types of cancers.
AZD4547 (CAS 1035270-39-3) References
- FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. | Xie, L., et al. 2013. Clin Cancer Res. 19: 2572-83. PMID: 23493349
- Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. | Liu, L., et al. 2014. Cell Physiol Biochem. 33: 633-45. PMID: 24642893
- Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells. | Kwak, Y., et al. 2015. Mol Cancer Ther. 14: 2292-302. PMID: 26294741
- Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study. | Liang, D., et al. 2017. Drug Des Devel Ther. 11: 451-461. PMID: 28255231
- FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice. | Zhao, Q., et al. 2017. Sci Rep. 7: 11306. PMID: 28900173
- FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib. | Luo, H., et al. 2018. Oncol Rep. 39: 2270-2278. PMID: 29517107
- FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. | Wang, K., et al. 2018. Oncogene. 37: 5340-5354. PMID: 29858603
- Inhibition of Fibroblast Growth Factor Receptor by AZD4547 Protects Against Inflammation in Septic Mice. | Huang, Y., et al. 2019. Inflammation. 42: 1957-1967. PMID: 31321583
- AZD4547 Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting Inflammation: The Role of FGFR1 in Renal Tubular Epithelial Cells. | Chen, X., et al. 2020. Drug Des Devel Ther. 14: 833-844. PMID: 32161443
- Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models. | Phanhthilath, N., et al. 2020. Invest New Drugs. 38: 1677-1686. PMID: 32436058
- The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells. | Na, YR., et al. 2021. Int J Mol Sci. 22: PMID: 34639155
- Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs. | Cho, H., et al. 2021. Front Oncol. 11: 757598. PMID: 34790577
- AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. | Aytatli, A., et al. 2022. Cell Oncol (Dordr). 45: 41-56. PMID: 34837170
- AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy. | Feng, Y., et al. 2022. Anticancer Agents Med Chem. 22: 3107-3113. PMID: 35469578
- AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation. | Morales-Guadarrama, G., et al. 2022. J Steroid Biochem Mol Biol. 223: 106132. PMID: 35659529
Inhibitor of:
Bek, bFGF, Cadherin (CDH), Cnpy1, EGFL7, FGF-2, FGF-8F, FGFR, FGFR-3, FGFR-4, FGFR1OP2, FIBP, Fibroblast Growth Factor (FGF), FIGNL1, Flg, FRRS1, FRS3, GFR-1, N-cadherin, Olfr541, PCPTP1, PDZK11, and Tyrosine Kinase.Activator of:
Bek, Flg, FSD1, PRAT4B_Cnpy4, and Ron.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AZD4547, 5 mg | sc-364421 | 5 mg | $198.00 | |||
AZD4547, 10 mg | sc-364421A | 10 mg | $309.00 |